Accelerated Atherosclerosis in Rheumatoid Arthritis: Mechanisms and Treatment
-
Published:2019-07-09
Issue:9
Volume:25
Page:969-986
-
ISSN:1381-6128
-
Container-title:Current Pharmaceutical Design
-
language:en
-
Short-container-title:CPD
Author:
Reiss Allison B.1, Silverman Andrew1, Khalfan Muhammed1, Vernice Nicholas A.1, Kasselman Lora J.1, Carsons Steven E.1, De Leon Joshua1
Affiliation:
1. Winthrop Research Institute, Department of Medicine, NYU Winthrop Hospital, 101 Mineola Boulevard, Suite 4-004, Mineola, NY 11501, United States
Abstract
Background:Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disorder that increases the risk of developing cardiovascular disease. There is accumulating evidence that the RA disease state accelerates the formation of atherosclerotic plaques. Treatments for RA improve joint symptomatology and may reduce inflammation, but consideration of their effects on the cardiovascular system is generally low priority.Objective:Since cardiovascular disease is the leading cause of mortality in RA patients, the impact of RA therapies on atherosclerosis is an area in need of attention and the focus of this review.Results:The drugs used to treat RA may be analgesics, conventional disease-modifying anti-rheumatic drugs, and/or biologics, including antibodies against the cytokine tumor necrosis factor-α. Pain relievers such as nonselective non-steroidal anti-inflammatory drugs and cyclooxygenase inhibitors may adversely affect lipid metabolism and cyclooxygenase inhibitors have been associated with increased adverse cardiovascular events, such as myocardial infarction and stroke. Methotrexate, the anchor disease-modifying anti-rheumatic drug in RA treatment has multiple atheroprotective advantages and is often combined with other therapies. Biologic inhibitors of tumor necrosis factor-α may be beneficial in preventing cardiovascular disease because tumor necrosis factor-α promotes the initiation and progression of atherosclerosis. However, some studies show a worsening of the lipid profile in RA with blockade of this cytokine, leading to higher total cholesterol and triglycerides.Conclusion:Greater understanding of the pharmacologic activity of RA treatments on the atherosclerotic process may lead to improved care, addressing both damages to the joints and heart.
Funder
American Heart Association
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology
Reference191 articles.
1. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Arthritis Rheum, Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies.,, 2008, 59,, 1690-1697,[http://dx.doi.org/10.1002/art.24092] [PMID: 19035419] 2. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Semin Arthritis Rheum, Rheumatoid arthritis: a disease associated with accelerated atherogenesis.,, 2005, 35,, 8-17,[http://dx.doi.org/10.1016/j.semarthrit.2005.03.004] [PMID: 16084219] 3. Mozaffarian D, Benjamin EJ, Go AS. Circulation, Heart disease and stroke statistics--2015 update: a report from the American Heart Association.,, 2015, 131,, e29-e322,[http://dx.doi.org/10.1161/CIR.0000000000000152] [PMID: 25520374] 4. Fransen J, Kazemi-Bajestani SM, Bredie SJ, Popa CD. PLoS One, Rheumatoid arthritis disadvantages younger patients for cardiovascular diseases: a meta-Analysis.,, 2016, 11,, e0157360-,[http://dx.doi.org/10.1371/journal.pone.0157360] [PMID: 27310259] 5. Nurmohamed MT, Heslinga M, Kitas GD. Nat Rev Rheumatol, Cardiovascular comorbidity in rheumatic diseases.,, 2015, 11,, 693-704,[http://dx.doi.org/10.1038/nrrheum.2015.112] [PMID: 26282082]
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|